Skip to main content

Presbyopia

25
Pipeline Programs
24
Companies
50
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
10
0
8
6
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

24 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
10 programs
5
AcrySof IQ VivityPhase 4
acrysof ReSTORPhase 4
daily disposable multifocal contact lensPhase 4
lehfilcon APhase 45 trials
serafilcon APhase 41 trial
+5 more programs
Active Trials
NCT02403180Completed70Est. Jul 2015
NCT02235831Completed24Est. Oct 2014
NCT06053463Completed35Est. May 2024
+8 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
10 programs
1
4
4
1
AGN-190584Phase 41 trial
AGN-190584Phase 31 trial
Pilocarpine HClPhase 31 trial
Pilocarpine HCl Ophthalmic SolutionPhase 31 trial
VehiclePhase 31 trial
+5 more programs
Active Trials
NCT04403763Terminated80Est. Dec 2022
NCT05393089Withdrawn0Est. Apr 2023
NCT02197806Completed65Est. Nov 2014
+7 more trials
Orasis Pharmaceuticals
Orasis PharmaceuticalsIsrael - Herzliya
6 programs
3
3
CSF-1Phase 31 trial
CSF-1Phase 31 trial
CSF-1Phase 31 trial
CSF-1Phase 21 trial
PresbiDropsPhase 21 trial
+1 more programs
Active Trials
NCT03885011Completed166Est. Jul 2019
NCT02965664Completed36Est. Apr 2017
NCT02745223Completed36Est. Jun 2017
+3 more trials
ReVision Therapeutics
ReVision TherapeuticsNJ - Ridgewood
3 programs
1
Raindrop Near Vision InlayPhase 31 trial
Raindrop Near Vision InlayN/A1 trial
The Raindrop Near Vision InlayN/A1 trial
Active Trials
NCT03017612Terminated13Est. Dec 2016
NCT01373580Completed373Est. Dec 2016
NCT02668523Unknown400Est. Jul 2018
Sandoz
SandozAustria - Kundl
4 programs
2
UNR844Phase 21 trial
UNR844-ClPhase 21 trial
3% hydrogen peroxide solution with HydraGlyde® Moisture MatrixN/A1 trial
Opti-Free® PureMoist® contact lens solutionN/A1 trial
Active Trials
NCT02965833Completed126Est. Mar 2017
NCT02965820Completed122Est. Apr 2017
NCT04806503Terminated234Est. Oct 2022
+1 more trials
Zhaoke Ophthalmology
Zhaoke OphthalmologyChina - Guangzhou
1 program
1
BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; PlaceboPhase 21 trial
Active Trials
NCT06948357Recruiting119Est. Dec 2025
LENZ Therapeutics
LENZ TherapeuticsSOLANA BEACH, CA
9 programs
LNZ101PHASE_11 trial
Aceclidine+Brimonidine combination ophthalmic solutionPHASE_21 trial
Aceclidine+Brimonidine combination ophthalmic solutionPHASE_21 trial
Aceclidine+tropicamide combinationPHASE_21 trial
PRX-100PHASE_21 trial
+4 more programs
Active Trials
NCT06270030Completed21Est. Apr 2024
NCT05431543Completed59Est. Dec 2022
NCT05294328Completed68Est. Sep 2022
+6 more trials
Carl Zeiss Meditec
4 programs
Diagnostic deviceN/A1 trial
MEL90 excimer laser - PRESBYONDN/A1 trial
Standard, non-free-form, non-customized PAL spectaclesN/A1 trial
trifocal IOLN/A1 trial
Active Trials
NCT04037631Terminated24Est. May 2020
NCT06960785Not Yet Recruiting75Est. Feb 2026
NCT01234207Completed95Est. Oct 2009
+1 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
4 programs
Investigational contact lensN/A1 trial
LD118033 contact lensN/A1 trial
LD127025 MFN/A1 trial
kalifilcon A Daily Disposable MultifocalN/A1 trial
Active Trials
NCT01518868Completed126Est. Feb 2012
NCT01539694Completed126Est. Mar 2012
NCT01959178Completed146Est. Aug 2013
+1 more trials
Bracco
BraccoItaly - Milan
3 programs
Glasses to correct presbyopiaN/A1 trial
Presbyopia screening trainingN/A1 trial
Reading glassN/A1 trial
Active Trials
NCT05510687Active Not RecruitingEst. Apr 2026
NCT03001258CompletedEst. Jun 2015
NCT03719196CompletedEst. Dec 2018
Bausch + Lomb
Bausch + LombNJ - Bridgewater
3 programs
Investigational contact lensN/A
LD118033 contact lensN/A
LD127025 MFN/A
Novartis
NovartisBASEL, Switzerland
2 programs
3% hydrogen peroxide solution with HydraGlyde® Moisture MatrixN/A
Opti-Free® PureMoist® contact lens solutionN/A
TECLens
TECLensCT - Stamford
2 programs
Quantitative refractive crosslinkingN/A1 trial
Quantitative refractive crosslinkingN/A1 trial
Active Trials
NCT07208604Not Yet Recruiting25Est. Aug 2026
NCT07137767Not Yet Recruiting25Est. Aug 2026
Labcorp
LabcorpBURLINGTON, NC
2 programs
SpectaclesN/A1 trial
SpectaclesN/A1 trial
Active Trials
NCT04629820Unknown800Est. Jun 2024
NCT04654013Unknown1,291Est. Jun 2025
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Acuvue Oasys for PresbyopiaN/A1 trial
Active Trials
NCT02228109Completed35Est. Apr 2015
Ophtec
OphtecNetherlands - Groningen
1 program
Artiflex PresbyopicN/A1 trial
Active Trials
NCT04632784Active Not Recruiting49Est. Nov 2026
Clerio Vision
Clerio VisionNY - West Henrietta
1 program
Clerio Vision LIRIC-modified Bifocal Contact LensN/A1 trial
Active Trials
NCT03653715Completed30Est. Oct 2018
STAAR Surgical
STAAR SurgicalCA - Lake Forest
1 program
EDOF ICLN/A1 trial
Active Trials
NCT03499821Completed41Est. Jul 2019
LENSAR
LENSARFL - Orlando
1 program
LensAR Laser SystemN/A1 trial
Active Trials
NCT01062412Terminated80Est. Oct 2011
Young BioPharma
Young BioPharmaMA - Lowell
1 program
Phacoemulsification with multifocal intraocular lensN/A1 trial
Active Trials
NCT02556944Unknown40Est. Apr 2016
Autonomous Therapeutics
1 program
bifocal IOLN/A1 trial
Active Trials
NCT04265846Unknown140Est. Nov 2022
Abbott
AbbottABBOTT PARK, IL
1 program
iDesign 1.3-PRESBY treatmentN/A1 trial
Active Trials
NCT02806726Terminated42Est. Nov 2017
Santen
SantenCA - Emeryville
1 program
0.1% STN1013600 ophthalmic solutionPHASE_21 trial
Active Trials
NCT05665387Completed79Est. Jul 2023
Glaukos
GlaukosALISO VIEJO, CA
1 program
Pilocarpine Ophthalmic Topical Cream, Dose 1PHASE_21 trial
Active Trials
NCT05124275Completed123Est. Sep 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieAGN-190584
LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution
LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution
LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution
LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution
Orasis PharmaceuticalsCSF-1
AbbViePilocarpine HCl
AbbVieAGN-190584
Orasis PharmaceuticalsCSF-1
Orasis PharmaceuticalsCSF-1
AbbViePilocarpine HCl Ophthalmic Solution
AbbVieVehicle
ReVision TherapeuticsRaindrop Near Vision Inlay
Zhaoke OphthalmologyBRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo
Santen0.1% STN1013600 ophthalmic solution

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 8,285 patients across 50 trials

Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses

Start: Dec 2022Est. completion: Jun 20230
Phase 4Withdrawn
NCT06045299LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

Start: Sep 2023Est. completion: Jan 2025300 patients
Phase 3Completed
NCT05728944LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution

Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

Start: Mar 2023Est. completion: Jan 2024229 patients
Phase 3Completed
NCT05753189LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Start: Feb 2023Est. completion: Feb 2024362 patients
Phase 3Completed
NCT05656027LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

Start: Dec 2022Est. completion: Jan 2024469 patients
Phase 3Completed

An Evaluation of the Safety of CSF-1 in Presbyopic Subjects

Start: Apr 2022Est. completion: Dec 2022178 patients
Phase 3Completed
NCT04983589AbbViePilocarpine HCl

A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

Start: Sep 2021Est. completion: Feb 2022230 patients
Phase 3Completed

A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age

Start: May 2021Est. completion: Dec 202143 patients
Phase 3Completed

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)

Start: Oct 2020Est. completion: Jan 2022304 patients
Phase 3Completed

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)

Start: Oct 2020Est. completion: Feb 2022309 patients
Phase 3Completed
NCT03857542AbbViePilocarpine HCl Ophthalmic Solution

A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

Start: Mar 2019Est. completion: Sep 2020427 patients
Phase 3Completed

Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

Start: Dec 2018Est. completion: Oct 2019323 patients
Phase 3Completed
NCT02668523ReVision TherapeuticsRaindrop Near Vision Inlay

A Clinical Trial to Evaluate a Corneal Inlay for the Improvement of Near and Intermediate Vision in Pseudophakic Presbyopic Subjects

Start: Dec 2015Est. completion: Jul 2018400 patients
Phase 3Unknown
NCT06948357Zhaoke OphthalmologyBRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo

Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients

Start: Mar 2025Est. completion: Dec 2025119 patients
Phase 2Recruiting
NCT05665387Santen0.1% STN1013600 ophthalmic solution

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

Start: Dec 2022Est. completion: Jul 202379 patients
Phase 2Completed
NCT05431543LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

Start: Aug 2022Est. completion: Dec 202259 patients
Phase 2Completed

Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia

Start: Jun 2022Est. completion: Apr 20230
Phase 2Withdrawn
NCT05294328LENZ TherapeuticsAceclidine+Brimonidine combination ophthalmic solution

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

Start: May 2022Est. completion: Sep 202268 patients
Phase 2Completed
NCT05124275GlaukosPilocarpine Ophthalmic Topical Cream, Dose 1

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

Start: Jan 2022Est. completion: Sep 2022123 patients
Phase 2Completed

A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

Start: Jun 2021Est. completion: Oct 2022234 patients
Phase 2Terminated

A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

Start: Apr 2019Est. completion: Dec 2019125 patients
Phase 2Completed

A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia

Start: Feb 2019Est. completion: Jul 2019166 patients
Phase 2Completed
NCT03201562LENZ TherapeuticsAceclidine+tropicamide combination

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Start: Apr 2017Est. completion: May 201858 patients
Phase 2Completed

Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects

Start: Dec 2016Est. completion: Apr 201736 patients
Phase 2Completed

Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia

Start: Jul 2016Est. completion: Jun 201736 patients
Phase 2Completed
NCT02780115AbbVieAGN-199201 ophthalmic solution

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

Start: May 2016Est. completion: Oct 2017151 patients
Phase 2Completed
NCT02595528AbbVieAGN-199201 ophthalmic solution

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

Start: Apr 2016Est. completion: Oct 2017163 patients
Phase 2Completed

Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Start: Sep 2015Est. completion: Nov 201520 patients
Phase 2Completed

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

Start: Jul 2014Est. completion: Nov 201465 patients
Phase 2Completed

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

Start: Jul 2020Est. completion: Dec 202280 patients
Phase 1/2Terminated

Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia

Start: Mar 2024Est. completion: Apr 202421 patients
Phase 1Completed
NCT07208604TECLensQuantitative refractive crosslinking

Open Label, Multi-center, Phase I Study of TECLens Quantitative Refractive Crosslinking in Presbyopia-Aged Patients.

Start: Sep 2025Est. completion: Aug 202625 patients
N/ANot Yet Recruiting
NCT07137767TECLensQuantitative refractive crosslinking

Quantitative Refractive Crosslinking in Presbyopia Aged Patients

Start: Aug 2025Est. completion: Aug 202625 patients
N/ANot Yet Recruiting
NCT06960785Carl Zeiss MeditecMEL90 excimer laser - PRESBYOND

Evaluation of Refractive Outcomes in Patients Undergoing PRESBYOND Using the MEL90 Excimer Laser

Start: May 2025Est. completion: Feb 202675 patients
N/ANot Yet Recruiting
NCT06469242Alconserafilcon A

Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Contact Lenses

Start: Jul 2024Est. completion: Oct 2024106 patients
N/ACompleted
NCT05510687BraccoGlasses to correct presbyopia

Transforming Households With Refraction and Innovative Financial Technology

Start: Dec 2023Est. completion: Apr 2026
N/AActive Not Recruiting
NCT06053463AlconDaily disposable multifocal soft contact lens

Evaluation of Soft Multifocal Lenses in Presbyopic Previous Contact Lens Wearers

Start: Oct 2023Est. completion: May 202435 patients
N/ACompleted

PROductivity Study of Presbyopia Elimination in Rural-dwellers II

Start: Aug 2023Est. completion: Jun 2024800 patients
N/AUnknown

PROductivity Study of Presbyopia Elimination in Rural-dwellers III

Start: May 2022Est. completion: Jun 20251,291 patients
N/AUnknown
NCT05325931Bausch Healthkalifilcon A Daily Disposable Multifocal

1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for Presbyopia

Start: Feb 2022Est. completion: Mar 202230 patients
N/ACompleted
NCT04632784OphtecArtiflex Presbyopic

Clinical Trial With Artiflex Presbyopic (Artiplus)

Start: Nov 2021Est. completion: Nov 202649 patients
N/AActive Not Recruiting
NCT04631796Alconlehfilcon A

Clinical Characterization of an Investigational Soft Silicone Hydrogel Contact Lens

Start: Dec 2020Est. completion: Dec 202036 patients
N/ACompleted
NCT04422990Alconlehfilcon A

Clinical Evaluation of a Silicone Hydrogel Daily Wear Monthly Replacement Contact Lens

Start: Oct 2020Est. completion: May 2021158 patients
N/ACompleted
NCT04476784Alconlehfilcon A

Clinical Assessment of a Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lens

Start: Aug 2020Est. completion: Nov 202066 patients
N/ACompleted
NCT04403542Alconlehfilcon A

Pilot Clinical Performance of a Silicone Hydrogel Lens for Up to Six Nights of Extended Wear

Start: Aug 2020Est. completion: Aug 202036 patients
N/ACompleted

Prospective Clinical Study of Different Intraocular Lens Implantation Designed for the Correction of Presbyopia

Start: May 2020Est. completion: Nov 2022140 patients
N/AUnknown
NCT04178720Alconlehfilcon A

Clinical Evaluation of a Daily Wear Monthly Replacement Silicone Hydrogel Lens

Start: Jan 2020Est. completion: Jun 2020119 patients
N/ACompleted
NCT04474782AlconThere is not an intervention

Analysis of Defocus Curve of Pre-Presbyopic and Emerging Presbyopic Patients

Start: Oct 2019Est. completion: Aug 202045 patients
N/ACompleted
NCT04055519Alconlehfilcon A

Clinical Performance Assessment of a Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lens

Start: Sep 2019Est. completion: Dec 201936 patients
N/ACompleted

Visual Outcomes After Presbyopic Lens Exchange

Start: May 2019Est. completion: Dec 201936 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

8 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 8,285 patients
24 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.